Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 27 Novo Nordisk has a strong leadership position within the growing diabetes care market Global diabetes care market by treatment class Global diabetes care value market share Novo Nordisk AstraZeneca Sanofi Novartis Eli Lilly Merck Takeda GSK 27% DKK billion OAD GLP-1 Insulin 450 30% 400 Total market: CAGR¹ 14.9% 350 300 Injectables: 20% CAGR¹ 19.5% 250 200 150 100 50 Aug 2006 1 CAGR for 10-year period OAD: Oral Anti-diabetic Source: IMS Monthly MAT August, 2016 value figures CAGR¹ 18.0% CAGR¹ 10.1% 0% Aug Aug 2016 2006 10% Source: IMS Monthly MAT August, 2016 value figures changing diabetes® Aug 2016 novo nordisk

View entire presentation